TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06301737

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive rehabilitation
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: the patients were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT05982470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Gel
Description: Estradiol gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Placebo Gel
Description: Estradiol placebo gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Soft Capsule
Description: Progesterone soft capsules 100mg once daily (oral) for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone Placebo Soft Capsule
Description: Progesterone placebo soft capsules 100mg once daily (oral) for 12 months
Study: NCT06015724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: anti-CD38 monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: anti-CD38 monoclonal antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRAS vaccine
Description: Stimulon QS-21 and Targovax TG01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRAS vaccine
Description: Stimulon QS-21 and Targovax TG01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
Study: NCT05754905

Intervention type: OTHER
Intervention: Magnetic resonance examination
Description: the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence

Intervention type: OTHER
Intervention: Magnetic resonance examination
Description: the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
Study: NCT06572436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia information training
Description: The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
Study: NCT05739058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Violet-Blue Light Treatment / FlashHeal Device
Description: FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Violet-Blue Light Treatment / FlashHeal Device
Description: FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Violet-Blue Light Treatment / FlashHeal Device
Description: FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz.
Study: NCT06447038

Intervention type: DIAGNOSTIC_TEST
Intervention: albumin creatinine ratio
Description: Albumin creatinine ratio, this test is routinely performed in urine.
Study: NCT06662604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cells concentrate , platelet rich fibrin , bone graft
Description: All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin and bone graft
Description: All participants will treated with platelet rich fibrin PRF , bone graft.
Study: NCT06379841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Green Draping Procedure
Description: The green draping will include only an under-buttock. After normal hand hygiene and scrub, the green draping procedure will have the surgeons don only a single pair of sterile gloves.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Draping Procedure
Description: The full draping will include under-buttocks, two-leg drapes, blue towels, and a top drape. After normal hand hygiene and scrub, the draping procedure will have the surgeon don a surgical gown and two sets of sterile gloves for the surgeon.
Study: NCT06670404

Intervention type: DEVICE
Intervention: Vertebroplasty
Description: Vertebral compression fractures treated with CONFIDENCE High Viscosity Cement
Study: NCT05802745

Intervention type: OTHER
Intervention: Reintubation
Description: Patients requiring re-intubation for acute respiratory failure.
Study: NCT06669013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinutuximab beta
Description: Chemotherapy + Immunotherapy (dinutuximab beta)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinutuximab beta
Description: Chemotherapy + Immunotherapy (dinutuximab beta)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinutuximab beta
Description: Chemotherapy + Immunotherapy (dinutuximab beta)
Study: NCT05953883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor and blood sample
Description: Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
Study: NCT06352840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Pelvic Plan Website
Description: This is a self-directed program which integrates patient education about conditions that frequently contribute to pelvic pain, as well as instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Participants will have open access to the program over the 6-month intervention period. The intervention will be comprised of an active (12-week) phase and a maintenance (3-month) phase. Participants will receive a weekly text or email prompt directing patients to a specific module. All participants will receive prompts to the same modules for the first four weeks of the study, then during the next 8 weeks, participants will receive prompts to modules that corresponded to the most impactful symptoms on participant's baseline questionnaires. Following 12-week active phase, all participants will enter the maintenance phase.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group website
Description: Patients in the control group will undergo an active control intervention in which participants receive open access to a separate website that contains only the Monitoring Progress symptom tracker subpage over the 6-month study period. Control group participation will also be divided into an active (12-week) phase and a maintenance (3-month) phase. Similar to the intervention group, the control group will receive a weekly text (first 12 weeks) or email prompt directing them to a specific module or portion of the respective website. During the maintenance phase of the study, participants will receive monthly prompts to the Monitoring Progress subpage (without prompting to a specific symptom or activity).
Study: NCT04872127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proximal embolism protection device
Description: a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: distal embolism protection device
Description: a distal SpiderFX will be used as the embolism protection device during CAS
Study: NCT05946382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RNT-ACT Protocol
Description: Swedish Translation of the 2\*60 minute Acceptance and Commitment Protocol for Repetitive Negative Thinking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCBT Treatment
Description: Internet-based Cognitive Behavioral Therapy as mandatory routine care in Swedish Primary care and therefore considered Treatment as usual.
Study: NCT04349826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 20 mg/kg/day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 20 mg/kg/day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime
Description: cefixime 20-30 mg/kg/day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cefixime-matched placebo for 7 days
Study: NCT06241794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group M-TAPA
Description: Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Serratus Intercostal Plane Block and Rectus Sheath Block
Description: Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on the right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of rectus abdominis muscle while displacing the posterior fascia and peritoneum downward
Study: NCT05892965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
Study: NCT05779488

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: maca
Description: 2.25 g of Maca extract, twice per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.25 g of starch, twice per day for 12 weeks
Study: NCT05433688

Intervention type: DEVICE
Intervention: Robotic assisted gastric bypass surgery
Description: The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
Study: NCT05344560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism
Description: CONTROL Lens
Study: NCT04080427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo is administered just prior to weekly exposure sessions by the oral route and contains only dextrose in opaque capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 7.5 milligram oral capsule
Description: Dronabinol (7.5mg) is administered just prior to weekly exposure sessions by the oral route and is placed in an opaque capsule with dextrose filler.
Study: NCT06578000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Iontophoresis therapy (MgO4 will be applied to the active positive electrode and the treatment will be repeated twice a week for four weeks) + conventional therapy (Splint + Stretch + strength).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy (Splint + Stretch + strength) twice a week for six weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy (Splint + Stretch + strength) twice a week for six weeks
Study: NCT05710523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACE training
Description: The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-pharmacological therapies (NPT) training
Description: The standard NPT training encompasses a training on the non-pharmacological therapies' methodology. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.
Study: NCT06119386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rexon-Eye
Description: In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
Study: NCT05507268

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04973176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bougie
Description: Standard Bougie for endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexi-tip Bougie (P3 Medical Bristol,UK)
Description: Flexi-tip Bougie for endotracheal intubation
Study: NCT05802342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexose ganglioside sodium injection
Description: The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexose ganglioside sodium injection
Description: The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Monosialotetrahexose ganglioside sodium injection
Description: The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
Study: NCT05986214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VC-OPTIONS
Description: Participants will be enrolled in the Annie texting VC-OPTIONS protocol